Developer docs
API playgroundTry for free, no card

Search company profiles

Segmed

Full company profile

uuid0000ao5

Namestring
Segmed
Legal namestring
Segmed, Inc.
Websiteurl
segmed.ai
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Segmed operates a proprietary multimodal medical imaging data platform branded Openda that aggregates and de-identifies real-world imaging studies from a global network of 2,800+ healthcare partner sites across 50 U.S. states and 5 continents. The platform exposes approximately 150 million de-identified imaging studies spanning CT, MRI, X-ray, ultrasound, mammography, PET, SPECT, echocardiography, and DEXA modalities, with structured clinical data and radiology text available as longitudinal, device-diverse datasets. Core technical components include the Incognito de-identification pipeline (independently validated by a HIPAA Expert Determination), an LLM-based Data De-identification Playground, and a Quality Playground for AI model validation. The company holds SOC 2 Type II, ISO 27001, HIPAA, and GDPR certifications and positions its data as regulatory-grade for FDA submissions, claiming to have supported more than 35 FDA-cleared AI technologies.

Short descriptiontext

Segmed operates the Openda platform, providing de-identified multimodal medical imaging data and clinical datasets from a 2,800-site global network to pharmaceutical, medical device, and healthcare AI customers for regulatory-grade AI development and clinical research.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersStanford, United States
HQ citystring
Stanford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical imaging data, real-world evidence, clinical research data, healthcare AI datasets, de-identified imaging
Industry4 codes
PRIMARYHLACAIAC
Healthcare Data Integration, ETL/ELT & Pipeline Orchestration
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare Data Platforms, Warehousing & Governance
SECONDARYHLACABAM
Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability
SECONDARYHLAJANAM
Data Linkage, Registries & Longitudinal Cohort Surveillance
SECONDARYHLACAIAI
FHIR/HL7 Data Repositories & Canonical Data Models
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare Data Platforms, Warehousing & Governance
NAICS code2 codes
  • Other Scientific and Technical Consulting Services54169
  • Medical and Diagnostic Laboratories6215
SIC code1 code
  • Services-Computer Programming, Data Processing, Etc.7370
Product category
Healthcare Imaging Data Platform
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Data Licensing and Subscriptions
TypeSubscription Recurring
Description

Segmed licenses de-identified medical imaging data to pharmaceutical companies, medical device manufacturers, AI developers, and healthcare researchers through subscription agreements and one-time data licensing contracts. Pricing varies based on dataset size, modality, customization requirements, and regulatory use case.

segmed.ai
2Platform Access Fees
TypeSubscription Recurring
Description

Revenue generated through access to the Openda platform for data exploration, cohort identification, and dataset procurement. Enterprise customers typically purchase imaging datasets or data subscriptions with aligned dataset delivery tied to AI training, validation, and regulatory timelines.

flashpointvc.com
3Research Partnerships
TypeData Monetisation
Description

Segmed generates revenue through research partnerships with life sciences companies and healthcare providers, providing data access and analytics services for clinical development and AI innovation programs.

prnewswire.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
1Enterprise subscriptions for pharmaceutical, medtech, and AI companies requiring large-scale imaging datasets and regulatory-grade data access.
ModelSubscriptionBilling cadenceAnnual
Notes

Custom pricing based on dataset scope, modality selection, longitudinal requirements, and regulatory use case. Annual and multi-year contract options available.

segmed.ai
2Self-serve platform access for smaller research teams and academic institutions through Openda.
ModelSubscriptionBilling cadenceMonthly
Notes

Platform subscription with tiered access levels based on data exploration needs and dataset procurement requirements.

segmed.ai
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Openda
Description

Proprietary data platform for accessing real-world medical imaging data for research and AI development

segmed.ai
Core offering1 text field

Segmed provides a proprietary multimodal data platform called Openda that aggregates and de-identifies approximately 150 million medical imaging studies from 2,800+ healthcare partner sites globally. The company licenses access to these regulatory-grade, HIPAA/GDPR-compliant datasets—spanning CT, MRI, X-ray, ultrasound, mammography, PET, SPECT, echocardiography, and DEXA—to pharmaceutical, medical device, and AI healthcare companies for clinical research, AI model training, and FDA regulatory submissions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 35+ FDA-cleared AI technologies supported by Segmed's datasets
+3 more records
Product overview1 text field

Segmed offers a unified multimodal data platform called Openda that provides access to real-world medical imaging data and clinical insights for healthcare AI development and biopharmaceutical research. The platform includes solution modules for Life Sciences R&D, Medical Devices and AI R&D, Clinical Data Management, and Healthcare Providers, supported by tools like the LLM-based De-identification Playground and Quality Playground for AI validation. Segmed also provides specialized datasets including the DBT-2026 annotated breast imaging dataset, all designed to support FDA regulatory submissions and accelerate precision health innovation.

Product and service2 records
1Openda
CategoryData Platform
Description

Segmed's proprietary multimodal data platform providing access to approximately 150 million de-identified, regulatory-grade medical imaging studies across multiple modalities (CT, MRI, X-ray, ultrasound, mammography, PET, SPECT, echocardiography, DEXA) for healthcare AI development, biopharmaceutical research, and medical device innovation. Used by pharmaceutical, medtech, and AI companies for AI training, validation, and FDA regulatory submissions.

2DBT-2026 Annotated 3D Mammography Dataset
CategoryData Product
Description

Free open-source annotated Digital Breast Tomosynthesis (3D mammography) dataset released with iMerit and Advocate Health. Contains 558 female patients with biopsy-confirmed diagnoses (271 malignant, 287 benign), expert segmentation annotations in DICOM and JSON formats, and full de-identification for breast cancer AI research.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-05
Description

iMerit collaborated with Segmed and Advocate Health to release the largest open-source annotated breast tomosynthesis (3D mammography) dataset for AI research in breast cancer detection. The dataset comprises 558 female patients with biopsy-confirmed diagnoses (271 malignant, 287 benign). iMerit provided expert annotation and segmentation by domain specialists.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-05
Description

Advocate Health collaborated with Segmed and iMerit to provide imaging studies from their health system for the open-source breast tomosynthesis dataset. Advocate Health is one of the largest not-for-profit integrated health systems in the United States. Advocate Health also led Segmed's Series A funding round.

Strategic tierFlagshipTypeTechnology or IntegrationAnnounced on2026-02-25
Description

Segmed partnered with Verily to make its de-identified, diagnostic-grade medical imaging data available within Verily's precision health research platform (Pre Exchange and Workbench). The collaboration enables researchers to access breast cancer datasets with digital breast tomosynthesis exams from Segmed's platform of approximately 150 million de-identified imaging exams. The partnership aims to lower barriers for researchers in academia, life sciences, and healthcare AI to accelerate precision health research and diagnostics development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-03
Description

Segmed's real-world imaging data (RWiD) was integrated into Bayer's AI Innovation Platform to accelerate the development of AI-powered healthcare solutions. The partnership enables Bayer to leverage Segmed's diverse imaging datasets for pharmaceutical research and AI development.

Strategic tierCoreTypeTechnology or Integration
Description

Segmed collaborates with Microsoft on foundation model development for healthcare AI. At RSNA 2025, Segmed and Microsoft co-presented an AI Theater session on 'Preparing Medical Data for Foundation Models' and explored best practices for preparing clinical datasets for AI development while maintaining compliance and patient privacy.

6Beacon Health System
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Segmed announced partnership with Beacon Health System for medical data collaboration. Beacon Health System contributes imaging data to Segmed's platform for research and AI development purposes.

segmed.ai
Strategic tierSupportingTypeTechnology or Integration
Description

Segmed partnered with Datavant to provide deeper patient insights through advanced imaging data integration. The partnership enables linking Segmed's imaging data with other healthcare data sources for comprehensive patient insights.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

MAPI partnered with Segmed to transform medical data into clinical impact in Japan. The partnership aims to leverage global medical data to accelerate AI-powered healthcare in the Japanese market.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Sirona Medical is an AI-native radiology operating system that aggregates imaging data and embeds diagnostic AI tools. It represents an emerging competitor integrating imaging AI directly into radiologist workflows, overlapping with Segmed's medical imaging data value chain.

TypeBroad incumbent
Description

Datavant specializes in health data linkage and de-identification, connecting disparate datasets for life sciences and healthcare. Segmed has a partnership with Datavant, but Datavant also competes in supplying linked real-world data for evidence generation and AI development.

TypeDirect peer
Description

TriNetX operates a global health research network providing de-identified clinical data for trial feasibility, cohort identification, and real-world evidence. It overlaps directly with Segmed's pharma R&D and clinical research use cases across multiple therapeutic areas.

4Tempus Labs
TypeDirect peer
Description

Tempus provides a multi-modal data library (including imaging, clinical, and molecular data) for AI development and pharma R&D. It is the most direct competitor to Segmed in supplying enterprise healthcare data for AI training and clinical research, with overlapping customer base in biopharma and AI developers.

TypeDirect peer
Description

Owkin builds AI models on medical imaging and multi-modal patient data, federated across hospitals. It competes with Segmed in supplying imaging data for healthcare AI, particularly for biopharma R&D and clinical research, with a strong presence in European academic medical centers.

TypeDirect peer
Description

Aetion provides a real-world evidence analytics platform used by biopharma and regulators for treatment effect estimation and regulatory-grade analyses. It serves the same life sciences R&D customer base as Segmed, focused on regulatory-grade evidence generation from real-world data.

TypeDirect peer
Description

Flatiron Health aggregates de-identified oncology real-world data from clinics and EHRs for pharma evidence generation and FDA submissions. Like Segmed, it sells to biopharma for clinical development and RWE use cases, with comparable regulatory-grade data positioning.

TypeBroad incumbent
Description

IQVIA is the largest life sciences RWE and clinical data provider, with extensive enterprise pharma relationships and a broad portfolio spanning real-world data, clinical trial services, and technology platforms. It is a broader incumbent competing for the same pharma data and evidence-generation budgets that Segmed targets.

TypeEmerging player
Description

DeepHealth (acquired by Saama) provides AI-powered medical imaging solutions and curated datasets for clinical and research applications. It overlaps with Segmed in supplying imaging datasets for AI development, particularly in oncology and radiology use cases.

TypeBroad incumbent
Description

Health Catalyst offers a healthcare data and analytics platform for health systems and life sciences, including data warehousing and RWE capabilities. It overlaps with Segmed in healthcare data infrastructure and provider-sourced data monetization.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Segmed

Healthcare Imaging Data Platformsegmed.ai

Segmed operates the Openda platform, providing de-identified multimodal medical imaging data and clinical datasets from a 2,800-site global network to pharmaceutical, medical device, and healthcare AI customers for regulatory-grade AI development and clinical research.

What Segmed does

Segmed operates a proprietary multimodal medical imaging data platform branded Openda that aggregates and de-identifies real-world imaging studies from a global network of 2,800+ healthcare partner sites across 50 U.S. states and 5 continents. The platform exposes approximately 150 million de-identified imaging studies spanning CT, MRI, X-ray, ultrasound, mammography, PET, SPECT, echocardiography, and DEXA modalities, with structured clinical data and radiology text available as longitudinal, device-diverse datasets. Core technical components include the Incognito de-identification pipeline (independently validated by a HIPAA Expert Determination), an LLM-based Data De-identification Playground, and a Quality Playground for AI model validation. The company holds SOC 2 Type II, ISO 27001, HIPAA, and GDPR certifications and positions its data as regulatory-grade for FDA submissions, claiming to have supported more than 35 FDA-cleared AI technologies.

Segmed firmographics

Firmographics
Name
Segmed
Legal name
Segmed, Inc.
Website
https://segmed.ai
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Segmed operates the Openda platform, providing de-identified multimodal medical imaging data and clinical datasets from a 2,800-site global network to pharmaceutical, medical device, and healthcare AI customers for regulatory-grade AI development and clinical research.
Ownership category
akta.pro rank

Segmed industry classification

Industry
Product category
Healthcare Imaging Data Platform
NAICS
Other Scientific and Technical Consulting Services (54169), Medical and Diagnostic Laboratories (6215)
SIC
Services-Computer Programming, Data Processing, Etc. (7370)
akta.pro industry
PRIMARYHLACAIAC
Healthcare Data Integration, ETL/ELT & Pipeline Orchestration
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare Data Platforms, Warehousing & Governance
SECONDARYHLACABAM
Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability
SECONDARYHLAJANAM
Data Linkage, Registries & Longitudinal Cohort Surveillance
SECONDARYHLACAIAI
FHIR/HL7 Data Repositories & Canonical Data Models
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare Data Platforms, Warehousing & Governance

Keywords

  • Medical imaging data
  • Real-world evidence
  • Clinical research data
  • Healthcare AI datasets
  • De-identified imaging

Where Segmed is headquartered

Location

Headquarters

HQ city
Stanford
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Segmed business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Data Licensing and Subscriptions: Segmed licenses de-identified medical imaging data to pharmaceutical companies, medical device manufacturers, AI developers, and healthcare researchers through subscription agreements and one-time data licensing contracts. Pricing varies based on dataset size, modality, customization requirements, and regulatory use case.
  2. Platform Access Fees: Revenue generated through access to the Openda platform for data exploration, cohort identification, and dataset procurement. Enterprise customers typically purchase imaging datasets or data subscriptions with aligned dataset delivery tied to AI training, validation, and regulatory timelines.
  3. Research Partnerships: Segmed generates revenue through research partnerships with life sciences companies and healthcare providers, providing data access and analytics services for clinical development and AI innovation programs.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise subscriptions for pharmaceutical, medtech, and AI companies requiring large-scale imaging datasets and regulatory-grade data access.
SubscriptionMonthlySelf-serve platform access for smaller research teams and academic institutions through Openda.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Segmed product offering

Product offering

Core offering

Segmed provides a proprietary multimodal data platform called Openda that aggregates and de-identifies approximately 150 million medical imaging studies from 2,800+ healthcare partner sites globally. The company licenses access to these regulatory-grade, HIPAA/GDPR-compliant datasets—spanning CT, MRI, X-ray, ultrasound, mammography, PET, SPECT, echocardiography, and DEXA—to pharmaceutical, medical device, and AI healthcare companies for clinical research, AI model training, and FDA regulatory submissions.

Product overview

Segmed offers a unified multimodal data platform called Openda that provides access to real-world medical imaging data and clinical insights for healthcare AI development and biopharmaceutical research. The platform includes solution modules for Life Sciences R&D, Medical Devices and AI R&D, Clinical Data Management, and Healthcare Providers, supported by tools like the LLM-based De-identification Playground and Quality Playground for AI validation. Segmed also provides specialized datasets including the DBT-2026 annotated breast imaging dataset, all designed to support FDA regulatory submissions and accelerate precision health innovation.

Differentiator

Problem solved

Functional benefit

Brands

  • Openda: Proprietary data platform for accessing real-world medical imaging data for research and AI development

Products and services

  • Openda Segmed's proprietary multimodal data platform providing access to approximately 150 million de-identified, regulatory-grade medical imaging studies across multiple modalities (CT, MRI, X-ray, ultrasound, mammography, PET, SPECT, echocardiography, DEXA) for healthcare AI development, biopharmaceutical research, and medical device innovation. Used by pharmaceutical, medtech, and AI companies for AI training, validation, and FDA regulatory submissions.
  • DBT-2026 Annotated 3D Mammography Dataset Free open-source annotated Digital Breast Tomosynthesis (3D mammography) dataset released with iMerit and Advocate Health. Contains 558 female patients with biopsy-confirmed diagnoses (271 malignant, 287 benign), expert segmentation annotations in DICOM and JSON formats, and full de-identification for breast cancer AI research.

Quantifiable outcome

  • 35+ FDA-cleared AI technologies supported by Segmed's datasets
  • +3 more outcomes

Companies that use Segmed

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Segmed technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability8 records

Feature5 records

Segmed partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core, flagship and supporting.

  • iMeritcoreStrategic or Co-development Partner · 5 March 2026iMerit collaborated with Segmed and Advocate Health to release the largest open-source annotated breast tomosynthesis (3D mammography) dataset for AI research in breast cancer detection. The dataset comprises 558 female patients with biopsy-confirmed diagnoses (271 malignant, 287 benign). iMerit provided expert annotation and segmentation by domain specialists.
  • Advocate HealthcoreStrategic or Co-development Partner · 5 March 2026Advocate Health collaborated with Segmed and iMerit to provide imaging studies from their health system for the open-source breast tomosynthesis dataset. Advocate Health is one of the largest not-for-profit integrated health systems in the United States. Advocate Health also led Segmed's Series A funding round.
  • Verily (Alphabet)flagshipTechnology or Integration · 25 February 2026Segmed partnered with Verily to make its de-identified, diagnostic-grade medical imaging data available within Verily's precision health research platform (Pre Exchange and Workbench). The collaboration enables researchers to access breast cancer datasets with digital breast tomosynthesis exams from Segmed's platform of approximately 150 million de-identified imaging exams. The partnership aims to lower barriers for researchers in academia, life sciences, and healthcare AI to accelerate precision health research and diagnostics development.
  • BayercoreStrategic or Co-development Partner · 3 December 2024Segmed's real-world imaging data (RWiD) was integrated into Bayer's AI Innovation Platform to accelerate the development of AI-powered healthcare solutions. The partnership enables Bayer to leverage Segmed's diverse imaging datasets for pharmaceutical research and AI development.
  • MicrosoftcoreTechnology or IntegrationSegmed collaborates with Microsoft on foundation model development for healthcare AI. At RSNA 2025, Segmed and Microsoft co-presented an AI Theater session on 'Preparing Medical Data for Foundation Models' and explored best practices for preparing clinical datasets for AI development while maintaining compliance and patient privacy.
  • Beacon Health SystemsupportingStrategic or Co-development PartnerSegmed announced partnership with Beacon Health System for medical data collaboration. Beacon Health System contributes imaging data to Segmed's platform for research and AI development purposes.
  • DatavantsupportingTechnology or IntegrationSegmed partnered with Datavant to provide deeper patient insights through advanced imaging data integration. The partnership enables linking Segmed's imaging data with other healthcare data sources for comprehensive patient insights.
  • MAPIsupportingStrategic or Co-development PartnerMAPI partnered with Segmed to transform medical data into clinical impact in Japan. The partnership aims to leverage global medical data to accelerate AI-powered healthcare in the Japanese market.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Segmed competitors and assessment

Company assessment

Emerging players

  • Sirona Medical: Sirona Medical is an AI-native radiology operating system that aggregates imaging data and embeds diagnostic AI tools. It represents an emerging competitor integrating imaging AI directly into radiologist workflows, overlapping with Segmed's medical imaging data value chain.
  • DeepHealth (Saama): DeepHealth (acquired by Saama) provides AI-powered medical imaging solutions and curated datasets for clinical and research applications. It overlaps with Segmed in supplying imaging datasets for AI development, particularly in oncology and radiology use cases.

Broad incumbents

  • Datavant: Datavant specializes in health data linkage and de-identification, connecting disparate datasets for life sciences and healthcare. Segmed has a partnership with Datavant, but Datavant also competes in supplying linked real-world data for evidence generation and AI development.
  • IQVIA: IQVIA is the largest life sciences RWE and clinical data provider, with extensive enterprise pharma relationships and a broad portfolio spanning real-world data, clinical trial services, and technology platforms. It is a broader incumbent competing for the same pharma data and evidence-generation budgets that Segmed targets.
  • Health Catalyst: Health Catalyst offers a healthcare data and analytics platform for health systems and life sciences, including data warehousing and RWE capabilities. It overlaps with Segmed in healthcare data infrastructure and provider-sourced data monetization.

Direct peers

  • TriNetX: TriNetX operates a global health research network providing de-identified clinical data for trial feasibility, cohort identification, and real-world evidence. It overlaps directly with Segmed's pharma R&D and clinical research use cases across multiple therapeutic areas.
  • Tempus Labs: Tempus provides a multi-modal data library (including imaging, clinical, and molecular data) for AI development and pharma R&D. It is the most direct competitor to Segmed in supplying enterprise healthcare data for AI training and clinical research, with overlapping customer base in biopharma and AI developers.
  • Owkin: Owkin builds AI models on medical imaging and multi-modal patient data, federated across hospitals. It competes with Segmed in supplying imaging data for healthcare AI, particularly for biopharma R&D and clinical research, with a strong presence in European academic medical centers.
  • Aetion: Aetion provides a real-world evidence analytics platform used by biopharma and regulators for treatment effect estimation and regulatory-grade analyses. It serves the same life sciences R&D customer base as Segmed, focused on regulatory-grade evidence generation from real-world data.
  • Flatiron Health: Flatiron Health aggregates de-identified oncology real-world data from clinics and EHRs for pharma evidence generation and FDA submissions. Like Segmed, it sells to biopharma for clinical development and RWE use cases, with comparable regulatory-grade data positioning.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Segmed social profiles

Digital presence

Segmed compliance and trust

Trust signal

Compliance4 records

Segmed financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Segmed leadership team

Management profile

Number of profiles

Profiles7 records

Segmed funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Segmed M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Segmed

What does Segmed do?

Segmed provides a proprietary multimodal data platform called Openda that aggregates and de-identifies approximately 150 million medical imaging studies from 2,800+ healthcare partner sites globally. The company licenses access to these regulatory-grade, HIPAA/GDPR-compliant datasets—spanning CT, MRI, X-ray, ultrasound, mammography, PET, SPECT, echocardiography, and DEXA—to pharmaceutical, medical device, and AI healthcare companies for clinical research, AI model training, and FDA regulatory submissions.

Is Segmed a public or private company?

Segmed is a private company. It is classified as venture growth investor backed and is currently operating.

When was Segmed founded?

Segmed was founded in 2017. It employs 11 to 50 people.

Where is Segmed based?

Segmed is headquartered in Stanford, United States, in the North America region.

How does Segmed make money?

Three revenue lines are on record. Data Licensing and Subscriptions are the primary driver. The others are platform Access Fees and research Partnerships.

Who are Segmed's main competitors?

Emerging players on record are Sirona Medical and DeepHealth (Saama). Broad incumbents are Datavant, IQVIA and Health Catalyst. Direct peers are TriNetX, Tempus Labs, Owkin, Aetion and Flatiron Health.

Does Segmed have an API?

No public API is recorded for Segmed.

What industry is Segmed in?

Segmed's product category is Healthcare Imaging Data Platform. Its primary akta.pro industry code is HLACAIAC, Healthcare Data Integration, ETL/ELT & Pipeline Orchestration, with a secondary code of HLACABAM, Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity). Its NAICS code is 54169 and its SIC code is 7370.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireNucs AI and Segmed Partner to Build the Data Foundation for Precision OncologyNucs AI and Segmed announced a partnership to build a data foundation for precision oncology, combining Segmed's multi-institutional imaging and clinical data with Nucs AI's AI models. Segmed's library spans over 2,800 sites and 150 million imaging studies, and Segmed is making a strategic investment in Nucs AI. The companies will jointly develop registries and validation frameworks.Healthcare TodayComment: Why it is important to share dataiMerit, with Segmed and Advocate Health, released a de-identified 3D mammography dataset of 558 biopsy-confirmed exams. The dataset includes 271 malignant and 287 benign cases, validated by board-certified radiologists, and is available for non-commercial research. It aims to support AI models for early breast cancer detection.PrtimesThe medical AI promotion organization has partnered with Segmed to establish a partnership regarding the clinical utilization of medical data.MAPI and Segmed announced a strategic partnership to expand access to global medical data, enabling Japanese access to overseas medical imaging data from over 2,800 institutions. MAPI will support regulatory compliance and data licensing, aiming to accelerate medical AI development and support Japanese companies' overseas expansion.PR NewswireiMerit, Segmed, and Advocate Health Announce Free Annotated 3D Mammography Data Set to Advance AI Research in Breast Cancer DetectioniMerit, in collaboration with Segmed and Advocate Health, announced the release of the largest open-source annotated breast tomosynthesis (3D mammography) data set for AI research in breast cancer detection. The dataset comprises imaging studies from 558 female patients with biopsy-confirmed diagnoses, including 271 malignant and 287 benign cases, featuring an average tumor size of 1.34 cm with 85% of lesions smaller than 2 cm. The initiative aims to accelerate early detection by providing freely accessible, clinically validated data to researchers worldwide, with the goal of supporting radiologists and improving survival rates through AI-powered diagnostics.BioSpaceSegmed Partners with Verily to Expand Access to Real-World Imaging DataSegmed, Inc. announced a partnership with Verily to make its de-identified, diagnostic-grade medical imaging data available within Verily's precision health research platform. The initial dataset focuses on breast cancer with digital breast tomosynthesis exams, drawn from Segmed's platform of approximately 150 million de-identified imaging exams spanning multiple modalities. The collaboration aims to lower barriers for researchers in academia, life sciences, and healthcare AI to accelerate precision health research and diagnostics development.PR NewswireSegmed Partners with Verily to Expand Access to Real-World Imaging DataSegmed announced a partnership with Verily to provide access to real-world medical imaging and clinical data through Verily's platform, supporting precision health research. The collaboration will enable researchers to explore datasets that include various imaging modalities, focusing initially on breast cancer, to accelerate diagnostics and therapies.NewswiseSegmed Partners with Verily to Expand Access to Real-World Imaging DataSegmed, Inc. announced a partnership with Verily to provide researchers access to de-identified medical imaging and clinical data through Verily's precision health platform, Pre Exchange and Workbench. The initial dataset focuses on breast cancer patients who underwent digital breast tomosynthesis exams with biopsy-proven malignant lesions, drawn from Segmed's global imaging platform comprising approximately 150 million de-identified imaging exams across modalities including CT, MRI, X-ray, ultrasound, mammography, PET, SPECT, echocardiography, and DEXA. The collaboration aims to accelerate AI-powered precision health research by enabling secure, scalable access to real-world imaging and clinical data within trusted research environments for investigators across academia, life sciences, and healthcare AI.HIT ConsultantVerily Launches Self-Serve Access to Pre Platform with New Segmed and RefinedScience DatasetsAlphabet's Verily has launched a free, self-serve Standard tier for its Pre precision health platform, enabling researchers to instantly access its data catalog and trusted research environment using a Google account without traditional IT provisioning delays. The launch adds three specialized datasets to the platform: a longitudinal Acute Myeloid Leukemia dataset from RefinedScience covering over 300 patients, a real-world breast imaging database from Segmed with 558 digital breast tomosynthesis exams, and a CRISPR interference dataset from Transcripta Bio mapping gene knockdowns linked to rare diseases. Verily is applying a SaaS democratization strategy to clinical research, allowing researchers to spin up collaborative workspaces and bypass months of institutional red tape previously required to access datasets of this magnitude.TipranksSegmed Expands Nationwide Medical Imaging Data Platform, Supporting 35+ FDA-Cleared AI ToolsSegmed announced that as of 2025 it has scaled its medical imaging data platform to over 150 million de-identified imaging studies with coverage across all 50 U.S. states and users in 20 countries. The company's dataset is now supporting more than 35 FDA-cleared AI technologies, and Segmed has released an Impact Report outlining how its platform enables AI development, real-world evidence generation, and healthcare research at scale. This expansion positions Segmed as a key data infrastructure provider in healthcare AI, with potential for recurring revenue through data licensing and research partnerships.